25 December,2021 09:33 PM IST | New Delhi | PTI
Photo for representational purpose
The Drugs Controller General of India (DCGI) has granted emergency use authorisation to Bharat Biotech's Covaxin for children above 12 years with certain conditions, sources said on Saturday.
The Subject Expert Committee on Covid-19 of the CDSCO on October 12 after deliberating Bharat Biotech's EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions.
"The recommendations of the SEC were evaluated by another experts committee after which DCGI had sought additional data from the firm," a source said.
The DCGI gave its approval Friday, the source said.
ALSO READ
Bharat Biotech co-founder Dr. Krishna Ella awarded by Johns Hopkins
INSACOG data says 290 cases of Covid-19 variant KP.2, 34 cases of KP.1 detected
ICMR slams Covaxin study for poor methodology
2,100 cases of Covid sub-variant JN.1, its lineages detected in India: INSACOG
India reports 133 new COVID-19 cases, active tally at 1,389
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.
